Rohatgi measured PGLYRP-1 in 3222 subjects and reported for the first time that its circulating levels were associated with widespread subclinical atherosclerosis in humans; Among 2,443 patients without cardiovascular disease at baseline, elevated levels of circulating PGLYRP-1 at baseline were independently associated with an increased risk of a first ASCVD event (Rohatgi et al., 2009; Brownell et al., 2016), suggesting that the biological processes reflected by elevated PGLYRP-1 may be strongly associated with the development of clinical ASCVD. This evidence concerns the gene PGLYRP1 and atherosclerosis.